Our Unique Approach
Many forms and stages of cancer continue to elude control. Malignant cells adapt and exploit mutations and redundancies, so partial targeting leaves vulnerabilities. Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes.
At Olema, we are committed to improving outcomes for women with metastatic breast cancer. Our lead asset, palazestrant (OP-1250), is a novel investigational agent with combined activity as both an advanced complete estrogen receptor antagonist, (a next-generation CERAN), and a selective estrogen receptor degrader, or SERD, which we believe will drive deeper, more durable responses than currently available therapies.